News

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

  • MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025
    07/28/2025

Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why

  • If you are looking for stocks that are well positioned to maintain their recent uptrend, Metsera Inc. (MTSR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
    07/28/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Metsera, Inc. Common Stock (MTSR) can sell. Click on Rating Page for detail.

The price of Metsera, Inc. Common Stock (MTSR) is 32.7688 and it was updated on 2025-08-25 11:00:22.

Currently Metsera, Inc. Common Stock (MTSR) is in overvalued.

News
    
News

Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

  • The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
    Thu, Jul. 10, 2025

Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why

  • Metsera Inc. (MTSR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
    Thu, Jul. 10, 2025

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

  • The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
    Tue, Jun. 24, 2025

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

  • NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11 at 10:00 – 10:35 A.M. EDT. A live webcast and replay of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com.
    Tue, Jun. 10, 2025

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

  • Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.
    Mon, Jun. 09, 2025
SEC Filings
SEC Filings

Metsera, Inc. Common Stock (MTSR) - 8-K - Current report

  • SEC Filings
  • 07/28/2025

Metsera, Inc. Common Stock (MTSR) - 10-Q - Quarterly Report

  • SEC Filings
  • 07/28/2025

Metsera, Inc. Common Stock (MTSR) - 8-K - Current report

  • SEC Filings
  • 06/09/2025

Metsera, Inc. Common Stock (MTSR) - SCHEDULE 13G

  • SEC Filings
  • 06/03/2025

Metsera, Inc. Common Stock (MTSR) - 4

  • SEC Filings
  • 05/22/2025

Metsera, Inc. Common Stock (MTSR) - SCHEDULE 13G/A

  • SEC Filings
  • 05/12/2025

Metsera, Inc. Common Stock (MTSR) - 8-K - Current report

  • SEC Filings
  • 05/12/2025

Metsera, Inc. Common Stock (MTSR) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/12/2025

Metsera, Inc. Common Stock (MTSR) - 4

  • SEC Filings
  • 04/30/2025

Metsera, Inc. Common Stock (MTSR) - 3

  • SEC Filings
  • 04/30/2025

Metsera, Inc. Common Stock (MTSR) - 8-K - Current report

  • SEC Filings
  • 04/28/2025

Metsera, Inc. Common Stock (MTSR) - SEC STAFF LETTER

  • SEC Filings
  • 01/31/2025

Metsera, Inc. Common Stock (MTSR) - CORRESP

  • SEC Filings
  • 01/28/2025

Metsera, Inc. Common Stock (MTSR) - CORRESP

  • SEC Filings
  • 01/27/2025

Metsera, Inc. Common Stock (MTSR) - UPLOAD

  • SEC Filings
  • 01/21/2025

Metsera, Inc. Common Stock (MTSR) - CORRESP

  • SEC Filings
  • 01/10/2025

Metsera, Inc. Common Stock (MTSR) - UPLOAD

  • SEC Filings
  • 12/26/2024

Metsera, Inc. Common Stock (MTSR) - SEC STAFF LETTER

  • SEC Filings
  • 12/26/2024

Metsera, Inc. Common Stock (MTSR) - DRS/A

  • SEC Filings
  • 12/12/2024

Metsera, Inc. Common Stock (MTSR) - DRSLTR

  • SEC Filings
  • 12/11/2024

Metsera, Inc. Common Stock (MTSR) - UPLOAD

  • SEC Filings
  • 12/02/2024

Metsera, Inc. Common Stock (MTSR) - DRS

  • SEC Filings
  • 11/04/2024
More Headlines
News

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

  • Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime.
  • 06/09/2025

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

  • Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and  potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.
  • 06/09/2025

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

  • Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations
  • 06/05/2025

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

  • MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025
  • 05/12/2025

Metsera to Present at Bank of America 2025 Global Healthcare Conference

  • NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Bank of America 2025 Global Healthcare Conference on Wednesday, May 14 at 2:20 - 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT).
  • 05/08/2025

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

  • MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025
  • 03/26/2025

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

  • NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, from 1:10 – 1:40 p.m. ET.
  • 02/26/2025

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

  • Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed significant mean placebo-adjusted weight loss up to 11.3% without plateau after 12 weeks, with phase 2b and monthly dosing data expected in 2025. MET-233i, a long-acting amylin analog being explored in a phase 1 study, is expected to have a data release in mid-2025.
  • 02/26/2025

Insider Buying Surges in February, Especially in These 6 Stocks

  • In January, the number of notable insider purchases was somewhat muted.
  • 02/09/2025

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

  • NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions, announced the closing of its initial public offering of 15,277,778 shares of its common stock, at an initial public offering price of $18.00 per share, on February 3, 2025. In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share, and the closing of the offering of such additional shares. All of the shares of common stock were offered by Metsera. The aggregate gross proceeds from the offering of the initial shares and the additional shares described above, before deducting underwriting discounts and commissions and other offering expenses, were $316.2 million. Metsera's common stock is listed on the Nasdaq Global Select Market under the ticker symbol “MTSR.”
  • 02/05/2025

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

  • Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.
  • 02/01/2025

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

  • Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.
  • 01/31/2025

Weight-loss drug developer Metsera raises $275 million in US IPO

  • Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.
  • 01/30/2025

Metsera Announces Pricing of Initial Public Offering

  • NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions, today announced the pricing of its initial public offering of 15,277,778 shares of its common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Metsera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Metsera, are expected to be approximately $275.0 million, excluding any exercise of the underwriters' option to purchase additional shares. Metsera's common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “MTSR” on January 31, 2025. The offering is expected to close on February 3, 2025, subject to satisfaction of customary closing conditions. In addition, Metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts and commissions.
  • 01/30/2025

Metsera Readies $275 Million IPO For Obesity Treatments

  • Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and related conditions. The firm's lead candidate, MET-097i, is in Phase 2b trials, with preliminary results expected by mid-2025, but faces intense competition. Management plans to use IPO proceeds for clinical trials and operational expenses, with funds expected to last until 2027.
  • 01/28/2025
Unlock
MTSR Ratings Summary
MTSR Quant Ranking